We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QADR
601
QDRO Acquisition Corp
QADR
$250M
| $14.9M | 0.02% |
+1,500,000
| New | +$14.9M |
|
602
Karyopharm Therapeutics
KPTI
$38.3M
| $14.9M | 0.02% |
1,521,322
-285,000
| -16% | -$2.47M |
|
603
Five Star Bancorp
FSBC
$1.13B
| $14.9M | 0.02% |
305,181
-203,146
| -40% | -$8.56M |
|
604
Xylem
XYL
$25.1B
| $14.8M | 0.02% |
125,143
-93,050
| -43% | -$10.7M |
|
605
Tractor Supply
TSCO
$17.7B
| $14.8M | 0.02% |
467,400
-6,000
| -1% | -$207K |
|
606
GE HealthCare
GEHC
$29.4B
| $14.7M | 0.02% |
+229,400
| New | +$15.1M |
|
|
TRAX
607
First Tracks Biotherapeutics
TRAX
$1.41B
| $14.7M | 0.02% |
+729,000
| New | +$13.6M |
|
|
FDXF
608
FedEx Freight
FDXF
$18.7B
| $14.6M | 0.02% |
+96,852
| New | +$15.9M |
|
|
VACI
609
Viking Acquisition Corp I
VACI
$198M
| $14.6M | 0.02% |
1,425,000
-375,000
| -21% | -$3.82M |
|
610
Celanese
CE
$4.88B
| $14.5M | 0.02% |
315,000
+207,000
| +192% | +$12M |
|
611
DuPont de Nemours
DD
$17.3B
| $14.5M | 0.02% |
106,799
+99
| +0.1% | +$14.1K |
|
612
Wintrust Financial
WTFC
$10.2B
| $14.5M | 0.02% |
90,000
-27,200
| -23% | -$4.09M |
|
613
Kraft Heinz
KHC
$29.2B
| $14.4M | 0.02% |
610,932
-11,500
| -2% | -$265K |
|
614
Tyson Foods
TSN
$18.2B
| $14.4M | 0.02% |
251,455
-200
| -0.1% | -$12.5K |
|
|
PTACU
615
Patriot Acquisition Corp Units
PTACU
$201M
| $14.4M | 0.02% |
+1,440,000
| New | +$14.4M |
|
616
Nordson
NDSN
$17.5B
| $14.2M | 0.02% |
47,200
| – | – |
|
617
Textron
TXT
$13.7B
| $14.2M | 0.02% |
155,026
-400
| -0.3% | -$36.3K |
|
|
WBS
618
DELISTED
Webster Financial
WBS
| $14.2M | 0.02% |
186,000
-375,000
| -67% | -$27.3M |
|
619
Albemarle
ALB
$14.9B
| $14.2M | 0.02% |
105,079
-100
| -0.1% | -$17.6K |
|
620
Brixmor Property Group
BRX
$8.87B
| $14.2M | 0.02% |
450,000
-10,000
| -2% | -$305K |
|
621
IQVIA
IQV
$42.3B
| $14.1M | 0.02% |
73,096
+15,244
| +26% | +$2.66M |
|
622
AutoNation
AN
$6.92B
| $13.9M | 0.02% |
75,000
-100,000
| -57% | -$19.6M |
|
623
Regions Financial
RF
$25.5B
| $13.9M | 0.02% |
460,500
+446,100
| +3,098% | +$12.5M |
|
624
Ralph Lauren
RL
$20B
| $13.8M | 0.02% |
34,426
-163,100
| -83% | -$60.7M |
|
|
NTST
625
NETSTREIT Corp
NTST
$2.03B
| $13.7M | 0.02% |
650,000
-20,000
| -3% | -$405K |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.